Document Detail

Pyrazolo[3,4-b]pyridine kinase inhibitors: a patent review (2008--present).
MedLine Citation:
PMID:  23289383     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Numerous heterocycles occur as recurring motifs in the design of kinase inhibitors. Pyrazolo[3,4-b]pyridine has proved particularly versatile due to its ability to interact with kinases via multiple binding modes. As such, this scaffold has been claimed for kinase inhibition in many patents originating from several companies and universities, and these cover a broad range of kinase targets.
AREAS COVERED: Patents from 2008 to the present in which pyrazolo[3,4-b] pyridine is utilized as a key element for inhibitor binding are included. This scaffold typically binds to the hinge region of the kinase, but examples in which other key interactions are formed are included in this review. Articles published in peer-reviewed journals that supplement information provided in the patent literature are highlighted.
EXPERT OPINION: Several bicyclic heterocycles are capable of forming a hydrogen bond donor-acceptor pair. This interaction is common among kinase inhibitors, particularly at the hinge region. These heterocycles are elaborated to form additional interactions in the kinase pocket which provide potency and selectivity, and thus serve as key scaffolds in kinase inhibitor design. Pyrazolo[3,4-b]pyridine can be viewed as having elements of both pyrrolo[2,3-b]pyridine and indazole and can therefore achieve multiple kinase binding modes. This scaffold is often encountered in kinase inhibitors as a result. Examination of the patent literature suggests that in some cases this group is simply one of several hinge binders examined for a particular series. In other cases, the pyrazolo[3,4-b]pyridine appears to provide an advantage, either in terms of intellectual property, inhibitor activity, physical properties or synthetic flexibility.
Steve Wenglowsky
Related Documents :
20179103 - Active mek2 as a regulatory scaffold that promotes pin1 binding to bpgap1 to suppress b...
15896303 - Involvement of mek-erk signaling pathway in the inhibition of cell growth by troglitazo...
12667453 - Targeted recruitment of set1 histone methylase by elongating pol ii provides a localize...
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-06
Journal Detail:
Title:  Expert opinion on therapeutic patents     Volume:  23     ISSN:  1744-7674     ISO Abbreviation:  Expert Opin Ther Pat     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-15     Completed Date:  2013-08-09     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9516419     Medline TA:  Expert Opin Ther Pat     Country:  England    
Other Details:
Languages:  eng     Pagination:  281-98     Citation Subset:  IM    
Blueprint Medicines, 215 First Street, Cambridge, MA 02142 , USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bicyclo Compounds / metabolism,  pharmacology
Hydrogen Bonding
Patents as Topic
Phosphatidylinositol 3-Kinases / antagonists & inhibitors
Protein Kinase Inhibitors / metabolism,  pharmacology*,  therapeutic use
Protein Kinases / chemistry,  metabolism
Pyrazoles / metabolism,  pharmacology*,  therapeutic use
Reg. No./Substance:
0/Bicyclo Compounds; 0/Protein Kinase Inhibitors; 0/Pyrazoles; EC 2.7.-/Protein Kinases; EC 2.7.1.-/Phosphatidylinositol 3-Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute l...
Next Document:  Solid cancer mortality in the techa river cohort (1950-2007).